It would have been a great quarter for ultrasound vendor AdvancedTechnology Laboratories. The Bothell, WA, company last week reportedthat revenues climbed 8% for the second quarter, while incometripled over the same period a year ago. Unfortunately,
It would have been a great quarter for ultrasound vendor AdvancedTechnology Laboratories. The Bothell, WA, company last week reportedthat revenues climbed 8% for the second quarter, while incometripled over the same period a year ago.
Unfortunately, ATL was forced to take a whopping $29.6 millionone-time charge in the quarter to pay for a damage award grantedto SRI International in connection with a patent infringementcase the company filed against ATL. A U.S. District Court judgein May assessed ATL $27.9 million in damages in connection withthe case (SCAN 6/5/96). ATL is pursuing an appeal of the decision.
The litigation charge wiped out what would have been a netprofit of $3.5 million. Instead, ATL wound up with a net lossfor the period of $19.2 million, compared with net income of $836,000in the second quarter of last year, when ATL took a one-time chargerelated to its consolidation of Interspec. ATL recorded an incometax benefit for the most recent quarter of $6 million.
ATL's revenues were a bright spot for the company, climbingto $98.6 million, compared with $91.3 million in the same periodof 1995. The company's gross margin improved to 48.4% from 46.6%due to an improved product mix and cost reduction programs.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.